Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here, I think, is the point: If Dr. Lieu knew an announcement that TLD did not achieve desirable endpoints were imminent, she would not, at a Hall of Fame event, allow herself to be described as a "Brain Cancer Vaccine Neurosurgeon."
Careful.
Next pitch could produce a grand slam.
I SO hope you're right.
"The big reveal."
Every morning I fire up my laptop, hoping fantastic TLD news has been released in Europe and spreading like wildfire on Bloomberg, CNBC, Fox Business, WSJ and NYT websites. Mostly because of the hope it will represent to those seriously ill with brain cancer; partly because I'd really like to have financial success as a result of the hundreds of thousands of shares I've been accumulating for the past decade; and partly because I'd really like the shorts (especially the naked ones) and market makers who've facilitated them to have a breath-taking moment of fear and regret.
I truly believe it will happen some day soon.
Maybe tomorrow?
"Good buy" indeed.
I increased my significant holdings by 3 percent yesterday at $1.15. Feeling confident.
Sing it, Carly Simon: ANTICIPATION...!
Thanks for the reassuring counsel. I'm hanging in, though I thought we'd have TLD by this time last year. Management, I hope, has a pleasant surprise awaiting us and punishing news for those who've tried to take down NWBO.
You're scaring me, Doc. Sounds like you're on the edge of losing faith.
From yesterday's "The Guardian"...
A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered.
In a landmark trial, a cocktail of immunotherapy medications harnessed patients’ immune systems to kill their own cancer cells and prompted “a positive trend in survival”, according to researchers at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS foundation trust.
One patient, who was expected to die four years ago, told the Guardian of the “amazing” moment nurses called him weeks after he joined the study to say his tumour had “completely disappeared”. The 77-year-old grandfather is now cancer-free and spent last week on a cruise with his wife.
Scientists found the combination of nivolumab and ipilimumab medications led to a reduction in the size of tumours in terminally ill head and neck cancer patients. In some, their cancer vanished altogether, with doctors stunned to find no detectable sign of disease.
Combining the two immunotherapy drugs could prove an effective new weapon against several forms of advanced cancer, experts believe. Results from other trials of the drug combination have previously suggested similar benefits for terminally ill kidney, skin and bowel cancer patients.
I agree with the "thousand cuts." I've been in it for about 800 of them.
When NWBO spurts toward $2 again (which I expect soon), there will be that temptation to sell. IMHO patience will be rewarded, that long-time shareholders who've been waiting for payday will know not to turn loose of their shares for any price in the single digits. Agree?
Surely we are at the extreme end of the time period when news should be forthcoming.
And about the weakness this morning?
Doc: I so hope you're right. Could it be soon, please?
"...inducing a substantial and optimal clinical and/or anti-tumor immune response."
I like it!
Beautiful and creative photography. Optimism about nwbo pretty standard stuff.
Thank you. Really good insight.
Excellent and realistic assessment, Doc. Thank you.
Well stated, Flipper. Big investment of time, lives and, yes, money is on the line now and management has had lots of time to anticipate where the enemies of progress and advocates of greed could attack. I trust those weak links are being fortified and when TLD becomes public (hopefully soon) there is only reason to celebrate.
Interesting report and discussion here. Reason to remain optimistic and fully invested.
Don't you think we must be very, very close to the "right time" now? Or will I still be asking that question in 2022?
Thank you, Cherry Tree. Good read for those who need big picture prospective and/or continued confidence in what NWBO is on the edge of producing.
Trillium Therapeutics, a developer of cancer drugs, is selling at better than $17 per share today, up from its approximately $6 earlier this week. The reason? It's being purchased by Pfizer.
Just because a scientific journal's first release of an article might be online (as opposed to on paper) doesn't preclude a PR campaign coordinated with the release of TLD through a publication's website. Authors of the article almost certainly would know when (or about when) their article will first appear. The biotech firm could (and should) have all of its PR prepared and be ready to "pull the trigger" when the online article appears. An electronic news release would go to the important medical/science writers who understand the findings' importance. That release would include a link to the science journal's online article. And researchers should be available for interviews.
Merck's in the game:
Adagene Inc. (NASDAQ: ADAG) announced that it has entered into a third clinical trial collaboration and supply agreement with Merck & Co., Inc. (NYSE: MRK). The agreement includes an open-label, dose escalation and expansion clinical study of ADG106 in combination with Merck's Keytruda in advanced or metastatic solid and/or hematological malignancies.
Doc, it's all a matter of timing, of course. Linda has been on-deck for a long, long time...long enough, one hopes, to get the timing right.
A good reminder about Cofer Black, NWBO board member. Anyone with doubts about what he can do to bring attention to a ground-breaking medical development should take a moment to read about him on Wikipedia.
Ref your recollections of the WS Journal article that sent a small stock soaring: I had a couple hundred shares as a much younger person (thinking this was about 25 years ago?) and was running late to catch a plane. But I took a moment to check the market, found the stock had gone from nowhere to about $90 a share and rapidly fallen to $50. I promptly sold it all and when I got off the plane a couple hours later, its price stood in the $20 range. Don't recall the stock's name and don't know if it's still around today. But the lesson you offered in your post is one to remember. NWBO is a candidate for just such an experience, particularly with Mr. Black on-board. Our world is hungry for some exciting, positive news.
I give you permission to remind me at year's end of what you just predicted.
To sell at this price ($1.20), you must believe the price will again retreat to the $1 level. I don't think it will--not this close to TLD.
Well said, Doc logic. I could sell my substantial number of shares today and still more than double my investment. But I truly believe this has the potential of being a 10X, 20X, maybe 30 or 40X return. It's not fun watching the price slip toward $1 a share, but my belief that we are truly only weeks away from hearing the results of what might be standard-of-care altering research tempts me to buy even more shares at this price. It's not for those who may need to sell their shares next week to buy milk for the baby.
Thank you.
Yes, I'm frustrated with the price at this level and then I remind myself about how excited/pleased I was just 10 months ago when it moved through $1 and held there. Even now, we're substantially above that.
I'm very long on NWBO...will not sell at these levels--ever...and recommend other longs also hold tight lest they, imho, see a much higher price yet this year and experience regret.
Yes, September.
But of what year?
Kelly Anne Conway says there are "alternative facts."
Nice bounce on a dreary day.
Bought some at $1.43 in February; more at $1.39 in April; more at $1.55 in June and more at $1.25 today. Average per share price is about 54 cents, with purchases beginning more than a couple years ago. Patience has been required, but I feel good (very good) about having a lot of shares at that average price. Our moment will arrive--most unexpectantly.
For all the obvious reasons, I hope you're right.
Amazing (breaking) news...and just the kind of coverage I hope we will someday soon see concerning dcVAX...
New York Times
In a scientific milestone, researchers were able to use electrodes to tap into the speech areas of a paralyzed man's brain and display his words on a screen. The achievement, published on Wednesday in the New England Journal of Medicine, could eventually help many patients with conditions that remove their ability to talk.
Doc, do you think we'll see TLD by Labor Day?